Artelo Biosciences (ARTL) News Today $23.88 -4.62 (-16.21%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$24.26 +0.39 (+1.61%) As of 07/11/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ARTL Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Artelo Biosciences completes reverse stock split and reports ...2 hours ago | investing.comArtelo Biosciences Presents Preclinical Data on ART26.12 as ... - NasdaqJuly 11 at 12:44 PM | nasdaq.comARTL - Artelo Biosciences Inc Financials | MorningstarJuly 11 at 12:44 PM | morningstar.comMArtelo Biosciences (NASDAQ:ARTL) Upgraded at D Boral CapitalJuly 11 at 3:35 AM | americanbankingnews.comArtelo Biosciences stock soars after positive preclinical pain dataJuly 10 at 5:41 AM | investing.comArtelo Biosciences’ ART12.11 Shows Promising Antidepressant Effects in Preclinical StudyJuly 10 at 5:41 AM | msn.comArtelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society SymposiumJuly 9, 2025 | globenewswire.comArtelo Biosciences (NASDAQ:ARTL) Rating Increased to Buy at D. Boral CapitalJuly 9, 2025 | americanbankingnews.comArtelo Biosciences, Inc. Common Stock (ARTL) - NasdaqJuly 8, 2025 | nasdaq.comD. Boral Capital Upgrades Artelo Biosciences (ARTL)July 8, 2025 | msn.comArtelo Biosciences Stock Climbs on Positive Preclinical Efficacy for Depression Drug CandidateJuly 8, 2025 | marketwatch.comArtelo Biosciences Stock Soars 114% After Promising Depression Treatment DataJuly 8, 2025 | msn.comArtelo Biosciences Stock Soars On Strong Preclinical Data In Par With Zoloft For Experimental Depression DrugJuly 8, 2025 | msn.comArtelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression ModelJuly 7, 2025 | globenewswire.comARTL - Artelo Biosciences Inc Sustainability - MorningstarJuly 2, 2025 | morningstar.comMArtelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain - Seeking AlphaJuly 2, 2025 | seekingalpha.comArtelo Biosciences Inc. (ARTL) Stock Price Today - WSJJune 30, 2025 | wsj.comArtelo Biosciences Stock Rises on Positive Trial Data for Treatment for Persistent PainJune 30, 2025 | marketwatch.comArtelo Biosciences stock soars after positive first-in-human study resultsJune 30, 2025 | za.investing.comArtelo Biosciences Stock Doubles After Positive Results In First Non-Opioid Pain Treatment TrialJune 30, 2025 | msn.comArtelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent PainJune 30, 2025 | globenewswire.comArtelo Biosciences, Inc. (ARTL) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comArtelo Biosciences Announces $1.425 Million At-the-Market Private Placement FinancingJune 26, 2025 | globenewswire.comArtelo Biosciences Announces Reverse Stock SplitJune 11, 2025 | globenewswire.comArtelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain StudyJune 5, 2025 | globenewswire.comNew Independent Review Paper Strengthens Therapeutic Rationale for Artelo’s FABP Inhibitor Program in Anxiety and DepressionJune 3, 2025 | finance.yahoo.comNew Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and DepressionJune 2, 2025 | globenewswire.comArtelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | finance.yahoo.comEXCLUSIVE: Artelo Biosciences' New Peer-Reviewed Research Shows Effectiveness Of Psoriasis Candidate In Animal ModelsApril 28, 2025 | finance.yahoo.comArtelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating PsoriasisApril 28, 2025 | globenewswire.comArtelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025March 31, 2025 | globenewswire.comArtelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial ResultsMarch 3, 2025 | globenewswire.comArtelo Biosciences reports promising nonclinical CBD studyFebruary 14, 2025 | msn.comArtelo Biosciences announces new data on ART12.11February 14, 2025 | markets.businessinsider.comArtelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®February 14, 2025 | globenewswire.comArtelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, SwitzerlandFebruary 11, 2025 | globenewswire.comArtelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12January 13, 2025 | globenewswire.comOptimistic Buy Rating for Artelo Biosciences Based on Promising Developments in Cancer Anorexia TreatmentDecember 10, 2024 | markets.businessinsider.comArtelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related AnorexiaDecember 9, 2024 | globenewswire.comArtelo Biosciences to present key data on 3 development programsNovember 18, 2024 | markets.businessinsider.comArtelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development SummitNovember 18, 2024 | globenewswire.comArtelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration SymposiumNovember 13, 2024 | globenewswire.comArtelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” ProgramNovember 5, 2024 | globenewswire.comArtelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16thOctober 9, 2024 | globenewswire.comArtelo Biosciences shares initiated with Buy by EF HuttonOctober 3, 2024 | uk.investing.comBuy Rating on Artelo Biosciences Amidst Promising Clinical Advancements and Portfolio DiversificationSeptember 11, 2024 | markets.businessinsider.comArtelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comArtelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 13, 2024 | globenewswire.comArtelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 InhibitorJuly 15, 2024 | globenewswire.comArtelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society SymposiumJuly 3, 2024 | globenewswire.com Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Email Address ARTL Media Mentions By Week ARTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARTL News Sentiment▼0.401.01▲Average Medical News Sentiment ARTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARTL Articles This Week▼171▲ARTL Articles Average Week Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BioAtla News Chemomab Therapeutics News VYNE Therapeutics News Aytu BioPharma News Dare Bioscience News Relmada Therapeutics News Sol-Gel Technologies News DURECT News MIRA Pharmaceuticals News Natural Alternatives International News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARTL) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARTL Stock Alerts